Boston Scientific has entered a $455 million partnership with Blackstone Life Sciences to co-fund development of its VITALYST™ heart pump. This is the first time the companies have jointly funded a Boston Scientific product.
The VITALYST system is a next-generation miniature heart pump designed for minimally invasive use. It is intended to treat acute myocardial infarction cardiogenic shock (AMI-CS), a life-threatening condition in which the heart cannot pump enough blood to vital organs. The device aims to improve cardiac output and blood flow, with the potential to improve efficacy and safety compared with currently available technologies for these critically ill patients.
Boston Scientific plans a pivotal trial in 2027 and is targeting a 2030 launch. Blackstone would receive royalties on sales after the launch.